Autoimmune Disorders

Transform

Transform is an investigational study in patients with a 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness.

Primary disease category:

Secondary disease category(ies):

Autoimmune Disorders

A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

The purpose of this study is to evaluate the safety of different doses of risankizumab and determine how well it works in subjects with moderate to severe Crohn’s disease.

Primary disease category:

Digestive System

Secondary disease category(ies):

Autoimmune Disorders

A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the safety of different doses of risankizumab and determine how well it works in subjects with moderate to severe Crohn disease.

Primary disease category:

Digestive System

Secondary disease category(ies):

Autoimmune Disorders